EBI Acquires Xstim to Advance Bone Growth Stimulation

EBI, a prominent player in electrobiology and bone growth stimulation, has significantly expanded its therapeutic offerings through the strategic acquisition of Xstim. This move integrates Xstim, formerly a division of Precision Medical Products, into EBI's existing suite of non-surgical and implantable bone healing solutions. The transaction is set to enhance EBI's position as a dedicated specialist in the bone growth stimulation market.

The newly acquired Xstim technology represents a modern, wearable, and non-invasive approach to spinal fusion stimulation. Designed with patient comfort and ease of use as core tenets, this therapy utilizes capacitively coupled electrical stimulation to promote bone healing following lumbar spinal fusion procedures. This advancement is particularly relevant in a healthcare environment increasingly focused on improving patient experience and reducing hospital stays.

This integration is more than just an addition of a new product; it's a strategic enhancement of EBI's comprehensive portfolio. The company, backed by Avista Healthcare Partners, now offers an even more robust set of clinically validated options for surgeons and patients. These solutions address critical needs across lumbar spinal fusion, nonunion fracture repair, and failed joint fusion applications, solidifying EBI's role as a single-source provider for bone healing technologies.

The bone growth stimulation market is experiencing steady growth, driven by an aging population, increasing rates of orthopedic procedures, and a growing demand for less invasive treatment alternatives. EBI's acquisition of Xstim positions it to capitalize on these trends, offering advanced solutions that align with the evolving requirements of both healthcare providers and patients seeking improved bone healing outcomes. The company's existing FDA-approved products, such as the EBI Bone Healing System and SpinalPak, are now complemented by Xstim's innovative capabilities.

Kevin Kenny, Chief Executive Officer of EBI, emphasized the company's commitment to leadership in the sector. "Our vision is clear: to be the trusted market leader in bone growth stimulation, dedicated to partnering with physicians to improve their patients’ bone healing outcomes," Kenny stated. "The addition of Xstim further supports our mission by introducing next generation products, strengthening our portfolio and expanding our R&D pipeline focused on today’s modern needs for both surgeons and patients." This forward-looking statement underscores EBI's ambition to drive innovation and maintain its competitive edge.

The transaction saw significant advisory support, with William Blair acting as the exclusive financial advisor to Precision Medical Products, and Perkins Coie providing legal counsel. Ropes & Gray served as legal counsel to EBI. These professional services highlight the structured nature of such strategic acquisitions within the medtech sector.